Advancing Stem Cell Biology toward Stem Cell Therapeutics  by Scadden, David & Srivastava, Alok
Cell Stem Cell
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toward Stem Cell TherapeuticsHere, the International Society for Stem Cell Research (ISSCR) Clinical Translation Committee introduces
a series of articles outlining the current status, opportunities, and challenges surrounding the clinical trans-
lation of stem cell therapeutics for specific medical conditions.Stem cells are valuable tools for the study of developmental
biology, drug discovery, the development of diagnostics, and
modeling and understanding disease, and they also show
tremendous potential for the development of scientifically sound
stem-cell-based therapies. The International Society for Stem
Cell Research (ISSCR) is dedicated to the advancement of
stem cell science and its applications, and the ISSCR Clinical
Translation Committee, which consists of individuals who have
awide range of experience in areaswhere the clinical application
of stem cells is either imminent or in place, has been given the
twin mandate of (1) promoting clinical research and therapeutic
application of stem cells, and (2) taking steps to prevent the
exploitation of vulnerable patients receiving unproven stem cell
treatments outside of well-regulated clinical trials. To help
address the first of thesemandates, we will publish, in the ISSCR
section of Cell Stem Cell, a series of white papers that take
a disease-specific approach to address particular concerns
surrounding the study, feasibility, and efficacy of stem-cell-
based treatments.Figure 1. Steps in the Translation of Stem Cell Research to Cell Thera
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steps along the translation pathway.At present, physicians and scientists around the world are
attempting to bring stem cells and stem-cell-derived products
to clinical applications. The responsible development of such
approaches requires the rigorous scientific investigation and
testing of stem cells and their applications in both preclinical
and clinical studies (see Figure 1). Moving ‘‘from bench to
bedside’’ is complex and time-consuming, a reality often not
evident to either the clinician or the patient given the rapid
advancement of the stem cell field from a basic research
perspective. Stem cells and their derivatives currently form the
basis of therapies for treating a select number of conditions,
including hematopoietic stem cell transplants for bone marrow
diseases and the use of epithelial-stem-cell-based treatments
for skin and corneal disorders and burns; and there are many
clinical trials underway investigating the possible use of different
cell types for a wide range of diseases. However, for most
other conditions for which stem cells have the potential to be
beneficial, they have not yet been shown to be so in appropri-
ately conducted clinical trials.peutics: From Bench to Bedside
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ISSCR Committee ForumTo provide a framework for the responsible and timely devel-
opment of clinically useful stem-cell-based treatments, the
ISSCR Clinical Translation Task Force developed the ‘‘ISSCR
Guidelines for the Clinical Translation of Stem Cells’’ (ISSCR,
2008). These guidelines provide a set of recommendations for
researchers, clinicians, and oversight groups to aid their deci-
sion-making and include discussions on topics such as adoption
of goodmanufacturing practices, importance and role of preclin-
ical studies, and proper conduct and oversight of the clinical
trial process. However, each disease or disorder that can poten-
tially be treated by stem-cell-based treatments also presents
a unique set of challenges and opportunities that cannot be
reduced to a single set of guidelines. These disease-specific
issues are the focus of this series of white papers. In this issue
of Cell Stem Cell, we present the first article in the series
describing the potential use of stem cells to treat neurodegener-
ative disorders.
For each area of application, we look at the approaches being
used to translate stem cell science to the clinic, with a particular
focus on the development of cell therapeutics. Each article will
therefore aim to do the following:
provide a summary of our knowledge about the disease and
the limitations of currently available therapies;150 Cell Stem Cell 10, 149–150, February 3, 2012 ª2012 ISSCRdescribe the preclinical models for their evaluation and limita-
tions of the data available so far;
suggest what stem cells or derivatives could provide themost
effective treatment and the need for their clear definition;
discuss the current state of clinical trials, including the
requirements for a successful stem-cell-based therapy to
be considered successful; and
explore potential directions for future investigation and
suggest specific and prioritized steps that must be taken
for the field to move forward.
By gathering a subset of leaders in areas where the clinical
application of stem cells is envisioned, the goal of the ISSCR is
to initiate action, foster debate, and provide a set of guideposts
for moving the field forward. Our hope is that, by providing these
starting points, we will be better positioned to shape, rework,
and test stem cell applications to specific patient needs. It is
through this process that we hope to foster the creation of effec-
tive stem cell treatments from the promise of stem cell science.
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